IDO on the re­bound? Dan­ish out­fit IO Biotech hopes so with over­sub­scribed Se­ries B one month af­ter BTD in melanoma

Less than a month af­ter achiev­ing break­through ther­a­py des­ig­na­tion in melanoma, IO Biotech has se­cured an over­sub­scribed Se­ries B that will help them get their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER